{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:18:07Z","timestamp":1788322687274,"version":"build-2803163510"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Clinical studies of T cells engineered with chimeric antigen receptor (CAR) targeting CD19 in B-cell malignancies have demonstrated that relapse due to target antigen (CD19) loss or limited CAR T cell persistence is a common occurrence. The possibility of such events is greater in solid tumors, which typically display more heterogeneous antigen expression patterns and are known to directly suppress effector cell proliferation and persistence. T cell engineering strategies to overcome these barriers are being explored. However, strategies to simultaneously address both antigen heterogeneity and T cell longevity, while localizing anti-tumor effects at disease sites, remain limited. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study we explore a dual antigen targeting strategy by directing independent CARs against the solid tumor targets PSCA and MUC1. To enhance functional persistence in a tumor-localized manner, we expressed the transgenic IL-7 cytokine and receptor (IL-7R\u03b1) in respective CAR products. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This binary strategy, which incorporates dual antigen targeting with transgenic cytokine support, resulted in enhanced potency, T cell expansion, and durable antitumor effects in a pancreatic tumor model compared to single antigen targeting or dual antigen targeting in absence of the transgenic cytokine support.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The transgenic IL-7 armed binary CAR T cell approach could improve the efficacy of CAR-based therapies for solid tumors.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1618404","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T05:30:04Z","timestamp":1753853404000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["IL-7 armed binary CAR T cell strategy to augment potency against solid tumors"],"prefix":"10.3389","volume":"16","author":[{"given":"Alejandro G.","family":"Torres Chavez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anmol","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Daga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Leen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradip","family":"Bajgain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: bright future or dark reality","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01740","article-title":"CAR T cells in solid tumors: blueprints for building effective therapies","volume":"9","author":"Knochelmann","year":"2018","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02593","article-title":"Making CAR T cells a solid option for solid tumors","volume":"9","author":"Schmidts","year":"2018","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: A translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.1038\/s41467-024-50251-x","article-title":"CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma","volume":"15","author":"Tian","year":"2024","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell Malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008572","article-title":"Tethered IL15-IL15Ralpha augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model","volume":"12","author":"Sanchez-Moreno","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0115","article-title":"Secreted fas decoys enhance the antitumor activity of engineered and bystander T cells in fas ligand-expressing solid tumors","volume":"10","author":"Bajgain","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.016","article-title":"Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer","volume":"25","author":"Mohammed","year":"2017","journal-title":"Mol Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzn055","article-title":"Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors","volume":"22","author":"Leyton","year":"2009","journal-title":"Protein Eng Des Sel"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5093","article-title":"Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors","volume":"14","author":"Leyton","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.7.4901","article-title":"Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor","volume":"180","author":"Wilkie","year":"2008","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910701)68:1<169::AID-CNCR2820680130>3.0.CO;2-R","article-title":"Multi-parameter flow cytometric quantitation of the expression of the tumor-associated antigen SM3 in normal and neoplastic ovarian tissues. A comparison with HMFG1 and HMFG2","volume":"68","author":"van Dam","year":"1991","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910280105","article-title":"Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers","volume":"28","author":"Arklie","year":"1981","journal-title":"Int J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb03596.x","article-title":"RD114-pseudotyped oncoretroviral vectors. Biological and physical properties","volume":"938","author":"Kelly","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpa.0000173459.81193.4d","article-title":"Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer","volume":"31","author":"Wente","year":"2005","journal-title":"Pancreas"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.670396","article-title":"Mucin-1 protein is a prognostic marker for pancreatic ductal adenocarcinoma: results from the CONKO-001 study","volume":"11","author":"Striefler","year":"2021","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e1253656","DOI":"10.1080\/2162402X.2016.1253656","article-title":"Fine-tuning the CAR spacer improves T-cell potency","volume":"5","author":"Watanabe","year":"2016","journal-title":"Oncoimmunology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40425-018-0347-5","article-title":"CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation","volume":"6","author":"Bajgain","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31720","article-title":"APC-derived cytokines and T cell polarization in autoimmune inflammation","volume":"117","author":"Gutcher","year":"2007","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and function of interleukin-2 in T lymphocytes","volume":"36","author":"Ross","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0307298101","article-title":"IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells","volume":"101","author":"Klebanoff","year":"2004","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3540","article-title":"An essential role for the IL-2 receptor in T(reg) cell function","volume":"17","author":"Chinen","year":"2016","journal-title":"Nat Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.965303","article-title":"IL-2 and IL-15 drive intrathymic development of distinct periphery-seeding CD4(+)Foxp3(+) regulatory T lymphocytes","volume":"13","author":"Apert","year":"2022","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737607","article-title":"IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3","volume":"38","author":"Imamichi","year":"2008","journal-title":"Eur J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408197102","article-title":"Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo","volume":"102","author":"Chen","year":"2005","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B35","first-page":"11","article-title":"Managing toxicities of high-dose interleukin-2","volume":"16","author":"Schwartz","year":"2002","journal-title":"Oncol (Williston Park)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3468","article-title":"IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion","volume":"25","author":"Conlon","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.str.2008.10.019","article-title":"Structural and biophysical studies of the human IL-7\/IL-7Ralpha complex","volume":"17","author":"McElroy","year":"2009","journal-title":"Structure"},{"key":"B38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.immuni.2004.07.016","article-title":"Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival","volume":"21","author":"Park","year":"2004","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803450","article-title":"IL-7 receptor expression provides the potential for long-term survival of both CD62Lhigh central memory T cells and Th1 effector cells during Leishmania major infection","volume":"182","author":"Colpitts","year":"2009","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121186","article-title":"Three-dimensional spheroids as in vitro preclinical models for cancer research","volume":"12","author":"Pinto","year":"2020","journal-title":"Pharmaceutics"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051075","article-title":"Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers","volume":"12","author":"Kailayangiri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0964","article-title":"CD19\/CD20 bispecific chimeric antigen receptor (CAR) in naive\/memory T cells for the treatment of relapsed or refractory non-hodgkin lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov"},{"key":"B44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41408-023-00819-5","article-title":"Which one is better for refractory\/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19\/CD22) CAR T-cell therapy","volume":"13","author":"Liu","year":"2023","journal-title":"Blood Cancer J"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27076","article-title":"Long-term follow-up of tandem CD19\/CD22 CAR T-Cells in r\/r B-ALL patients with high-risk features","volume":"98","author":"Cui","year":"2023","journal-title":"Am J Hematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25419","article-title":"How chimeric antigen receptor design affects adoptive T cell therapy","volume":"231","author":"Gacerez","year":"2016","journal-title":"J Cell Physiol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.684642","article-title":"Engineered cytokine signaling to improve CAR T cell effector function","volume":"12","author":"Bell","year":"2021","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.05.007","article-title":"Future perspectives on engineered T cells for cancer","volume":"10","author":"Posey","year":"2024","journal-title":"Trends Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040873","article-title":"IL7-IL12 engineered mesenchymal stem cells (MSCs) improve A CAR T cell attack against colorectal cancer cells","volume":"9","author":"Hombach","year":"2020","journal-title":"Cells"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discov"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/ng.924","article-title":"Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia","volume":"43","author":"Zenatti","year":"2011","journal-title":"Nat Genet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1175503","article-title":"3D cancer models: One step closer to in vitro human studies","volume":"14","author":"Manduca","year":"2023","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194846","article-title":"Three-dimensional in vitro tumor spheroid models for evaluation of anticancer therapy: recent updates","volume":"15","author":"Nayak","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B55","volume-title":"FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs","year":"2025"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1618404\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T05:30:05Z","timestamp":1753853405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1618404\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2025.1618404"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1618404","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"article-number":"1618404"}}